Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

FDA Fines Red Cross $16M For Screening Violations

By Drug Discovery Trends Editor | June 18, 2010

WASHINGTON (AP) – Federal health regulators fined the American Red Cross $16 million for sloppy screening of donated blood, the latest in a series of violations that have cost the group millions of dollars.

The Food and Drug Administration said in a statement that the group failed to take precautions to assure the safety of blood donations. Despite those oversights, the FDA says the U.S. blood supply appears to be safe.

Regulators fined the group nearly $10 million for mismanagement of blood products – including red blood cells, plasma and platelets – and over $6 million for faulty manufacturing practices. The violations occurred in fiscal years 2008 and 2009.

The FDA has cited the Red Cross a dozen times already and fined the group over $21 million since 2003.

Under the terms of a 2003 consent decree, the Red Cross pledged to investigate and correct its chronic blood safety violations.

“FDA is encouraged by recent efforts made by the Red Cross leadership,” the federal agency said in a statement, adding “the FDA is hopeful these fines will encourage the Red Cross to act more quickly to take the actions necessary to address and correct the issues.”

Last month a group representing Red Cross nurses alleged that staffing cuts, excessive work scheduling and mismanagement are responsible for many of the mistakes cited by the FDA over the years.

The Red Cross said in a statement that 98 percent of the violations cited by the FDA occurred before 2008, and that the group has made significant improvements since then.

“We appreciate the fact that the FDA has recognized that the Red Cross is making progress in improving compliance, but are disappointed that the FDA believed it necessary to fine us for prior violations dating back several years,” the group said.

The American Red Cross is one of several organizations that collect and manage the nation’s blood supply. The group provides about 43 percent of the U.S. blood supply, selling blood products to health facilities.

Date: June 17, 2010
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE